Breast Cancer Research & Therapies

About the conference

We are delighted to welcome you to the Breast Cancer Summit 2027, Breast Cancer Summit 2027 is a leading international platform dedicated to advancing research, innovation, and clinical excellence in breast cancer prevention, diagnosis, treatment, and survivorship. Centered on the theme "Advancing Precision Oncology and Innovation in Breast Cancer Care," the summit will bring together world-renowned oncologists, researchers, surgeons, radiologists, pathologists, healthcare professionals, pharmaceutical experts, academicians, industry leaders, and patient advocates from across the globe.

The conference is designed to promote scientific exchange, interdisciplinary collaboration, and the dissemination of the latest discoveries in breast cancer research. Participants will gain valuable insights into precision oncology, molecular diagnostics, targeted therapies, immunotherapy, AI-driven technologies, genetic profiling, personalized medicine, and emerging treatment strategies through keynote presentations, plenary lectures, scientific sessions, workshops, poster presentations, and panel discussions.

Breast Cancer Summit 2027 provides an exceptional opportunity to present groundbreaking research, engage with internationally recognized experts, establish meaningful collaborations, and explore innovative technologies that are transforming breast cancer care. The summit also offers a dynamic exhibition showcasing the latest advancements in medical devices, diagnostics,

Why Attend?

Inspiring Scientific Program: Discover the latest advances in precision oncology, targeted therapies, immunotherapy, early detection, AI-driven diagnostics, and personalized treatment strategies through keynote lectures, scientific sessions, panel discussions, and interactive workshops.

Global Networking Opportunities: Connect with leading experts, researchers, healthcare professionals, policymakers, and industry leaders to establish collaborations and share innovative ideas that shape the future of breast cancer care.

Exhibition and Industry Showcase: Explore cutting-edge technologies, diagnostic solutions, medical devices, pharmaceuticals, and research innovations presented by leading organizations and exhibitors from across the globe.

Professional Growth: Gain valuable insights from internationally recognized speakers, present your research, receive constructive feedback, and enhance your professional development while contributing to advancements in breast cancer treatment and patient outcomes.

Together, we will explore transformative innovations that are redefining breast cancer diagnosis, treatment, survivorship, and precision medicine. Join us in advancing scientific excellence and improving the lives of patients worldwide.

Call for Speakers, Delegates, Young Researchers, and Exhibitors: Submit your abstracts, register early, and become part of a global platform committed to "Advancing Precision Oncology and Innovation in Breast Cancer Care." We look forward to welcoming you to Breast Cancer Summit 2027.

Sessions and Tracks

Track 1: Precision Oncology in Breast Cancer

Precision oncology is transforming breast cancer management by tailoring prevention, diagnosis, and treatment to the unique molecular characteristics of each patient's tumor. Advances in genomic sequencing, biomarker discovery, and molecular profiling have enabled clinicians to identify actionable mutations and develop personalized treatment strategies that improve outcomes while minimizing toxicity. This track will highlight innovations in precision medicine, including liquid biopsy, next-generation sequencing, companion diagnostics, and AI-assisted clinical decision-making. Discussions will focus on translating genomic discoveries into clinical practice, optimizing targeted therapies, overcoming treatment resistance, and integrating precision oncology into routine breast cancer care. Experts will also explore emerging biomarkers, pharmacogenomics, and the future of individualized therapeutic approaches that are reshaping breast cancer management worldwide.

Track 2: Metastatic Breast Cancer

Metastatic breast cancer remains one of the greatest challenges in oncology, requiring innovative therapeutic strategies to improve survival and quality of life. This session will explore recent advances in systemic therapies, targeted treatments, antibody-drug conjugates, immunotherapy, and precision medicine approaches for advanced disease. Topics include mechanisms of metastasis, treatment sequencing, management of brain and bone metastases, resistance to therapy, and personalized treatment planning based on molecular profiling. Experts will discuss ongoing clinical trials, novel biomarkers, and multidisciplinary care models that enhance patient outcomes. The session also emphasizes supportive care, symptom management, survivorship, and emerging research aimed at transforming metastatic breast cancer into a more manageable chronic condition.

Track 3: Breast Cancer Biology and Tumor Microenvironment

Understanding the biological mechanisms driving breast cancer is fundamental to developing innovative therapies. This track focuses on tumor initiation, progression, cancer stem cells, molecular signaling pathways, epigenetic regulation, and interactions between tumor cells and their microenvironment. Discussions will examine immune cell infiltration, angiogenesis, stromal interactions, extracellular matrix remodeling, and mechanisms of therapeutic resistance. Emerging technologies such as single-cell sequencing, spatial transcriptomics, and multi-omics approaches are providing unprecedented insights into tumor biology. Participants will explore how these discoveries contribute to identifying novel therapeutic targets and advancing personalized treatment strategies for improved patient outcomes.

Track 4: Early Detection, Screening and Diagnosis

Early diagnosis remains the cornerstone of improving breast cancer survival. This session explores advances in breast cancer screening technologies, risk prediction models, imaging innovations, biomarker-based diagnostics, and genetic testing. Topics include digital mammography, breast MRI, contrast-enhanced imaging, ultrasound, AI-assisted image interpretation, liquid biopsy, and circulating tumor DNA analysis. Experts will discuss screening recommendations for average- and high-risk populations, hereditary cancer syndromes, and strategies to improve diagnostic accuracy while reducing false-positive findings. The session also addresses health equity, accessibility, and population-based screening initiatives designed to promote earlier detection and better clinical outcomes.

Track 5: Targeted Therapies and Personalized Treatment Strategies

Targeted therapies have revolutionized breast cancer treatment by selectively attacking molecular abnormalities while preserving healthy tissues. This track will highlight the latest developments in HER2-targeted therapies, CDK4/6 inhibitors, PARP inhibitors, PI3K inhibitors, endocrine therapy optimization, antibody-drug conjugates, and emerging targeted agents. Discussions will focus on biomarker-guided treatment selection, mechanisms of drug resistance, combination therapies, treatment sequencing, and individualized care pathways. Experts will also examine the integration of precision medicine into clinical practice, enabling clinicians to deliver more effective and less toxic therapies tailored to each patient's unique tumor profile.

Track 6: Breast Cancer Surgery and Reconstructive Oncology

Surgical management continues to evolve with advances that improve oncologic safety while preserving cosmetic and functional outcomes. This session covers breast-conserving surgery, mastectomy, sentinel lymph node biopsy, axillary management, oncoplastic surgery, robotic-assisted procedures, and reconstructive techniques. Participants will learn about multidisciplinary surgical planning, image-guided surgery, margin assessment technologies, enhanced recovery protocols, and shared decision-making. Discussions will also explore immediate and delayed breast reconstruction, patient-reported outcomes, quality-of-life considerations, and innovations that support personalized surgical care for patients across all stages of breast cancer.

Track 7: Radiation Oncology and Precision Radiotherapy

Radiation therapy remains a cornerstone of breast cancer treatment, with significant advancements improving precision, safety, and patient outcomes. This session will focus on modern radiotherapy techniques, including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiotherapy (SBRT), proton therapy, adaptive radiotherapy, and accelerated partial breast irradiation (APBI). Experts will discuss personalized radiation planning, treatment de-escalation strategies, toxicity management, and integration with systemic therapies. Emerging technologies, AI-driven treatment planning, and innovations in radiation oncology will also be explored, highlighting their role in maximizing tumor control while preserving healthy tissue and enhancing patients' quality of life.

Track 8: Clinical Trials and Translational Research

Clinical trials are essential for advancing breast cancer care by evaluating innovative therapies, diagnostics, and treatment strategies. This track will explore the latest developments in Phase I-IV clinical trials, precision oncology research, biomarker-driven studies, adaptive trial designs, and translational medicine. Discussions will focus on converting laboratory discoveries into effective clinical applications, improving patient selection through molecular profiling, and accelerating the development of novel therapeutics. Participants will gain insights into regulatory considerations, real-world evidence, international collaborations, and patient-centered trial design, emphasizing the importance of research in shaping the future of personalized breast cancer treatment.

Track 9: Male Breast Cancer

Although uncommon, male breast cancer presents unique clinical and biological challenges that require greater awareness and dedicated research. This session will examine epidemiology, genetic susceptibility, BRCA-associated cancers, diagnostic approaches, molecular characteristics, and evidence-based treatment strategies specific to male patients. Experts will discuss surgical management, systemic therapies, survivorship, psychosocial support, and the importance of early diagnosis. The session will also highlight ongoing clinical research, precision medicine approaches, and opportunities to improve outcomes through increased awareness, multidisciplinary care, and inclusion of male patients in breast cancer research initiatives.

Track 10: Breast Cancer During Pregnancy

Managing breast cancer during pregnancy requires careful coordination between oncology and maternal-fetal medicine specialists to ensure the best possible outcomes for both mother and child. This session will address diagnostic challenges, imaging considerations, surgical options, chemotherapy timing, targeted therapies, obstetric management, and postpartum care. Discussions will focus on evidence-based treatment recommendations, fertility preservation, ethical considerations, and multidisciplinary decision-making. Experts will also review current clinical guidelines, recent research findings, and long-term maternal and neonatal outcomes, providing valuable insights into delivering safe, personalized, and effective care throughout pregnancy.

Track 11: Oncology Nursing and Multidisciplinary Breast Cancer Care

Oncology nurses are integral members of the multidisciplinary team, providing patient-centered care throughout the breast cancer journey. This session will explore advances in symptom management, chemotherapy administration, survivorship planning, patient education, psychosocial support, palliative care, and quality-of-life improvement. Topics include evidence-based nursing practice, management of treatment-related toxicities, digital health integration, patient navigation, shared decision-making, and supportive care interventions. Participants will also discuss leadership in oncology nursing, professional development, and collaborative approaches that enhance treatment outcomes while addressing the physical, emotional, and social needs of patients and their families.

Track 12: Immunotherapy and Emerging Therapeutic Innovations

Immunotherapy is reshaping the future of breast cancer treatment by harnessing the body's immune system to recognize and eliminate cancer cells. This track will examine immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, antibody-drug conjugates, bispecific antibodies, CAR-T cell research, and combination treatment strategies. Discussions will focus on predictive biomarkers, tumor immunology, mechanisms of immune resistance, and strategies for improving therapeutic response. Experts will present the latest clinical evidence, ongoing research, and future directions in immuno-oncology, highlighting how innovative therapies are expanding treatment options and advancing precision medicine for patients with breast cancer.

Track 13: Artificial Intelligence and Digital Health in Breast Cancer

Artificial intelligence (AI) and digital health technologies are transforming breast cancer care by improving early detection, diagnostic accuracy, treatment planning, and patient monitoring. This track explores AI-driven imaging analysis, machine learning algorithms, digital pathology, radiomics, wearable health technologies, telemedicine, and predictive analytics. Experts will discuss the integration of big data, electronic health records, and clinical decision support systems to enhance precision oncology. Emerging innovations in digital biomarkers, remote patient monitoring, and AI-assisted personalized treatment planning will also be highlighted, demonstrating how technology is improving clinical outcomes, operational efficiency, and patient-centered care across the breast cancer continuum.

Track 14: Survivorship, Supportive Care and Quality of Life

As breast cancer survival rates continue to improve, comprehensive survivorship care has become an essential component of long-term patient management. This session focuses on survivorship planning, rehabilitation, symptom management, psychosocial support, fertility preservation, sexual health, nutrition, exercise, and management of treatment-related side effects. Discussions will examine patient-reported outcomes, mental health, palliative care, lifestyle interventions, and strategies for improving quality of life throughout survivorship. Experts will also address the role of multidisciplinary care teams in supporting patients beyond active treatment and promoting long-term physical, emotional, and social well-being.

Track 15: Cancer Prevention, Genetics and Risk Assessment

Understanding genetic predisposition and modifiable risk factors is fundamental to reducing the global burden of breast cancer. This track explores hereditary breast cancer syndromes, BRCA1/BRCA2 mutations, multigene panel testing, genetic counseling, polygenic risk assessment, lifestyle interventions, and preventive strategies. Participants will discuss advances in cancer screening, chemoprevention, risk prediction models, environmental influences, and population health initiatives. The session also highlights precision prevention approaches that integrate genomic information with personalized risk management to improve early detection and reduce breast cancer incidence.

Track 16: Triple-Negative, HER2-Positive and Hormone Receptor-Positive Breast Cancer

Breast cancer is a heterogeneous disease requiring subtype-specific treatment approaches. This session will examine the biology, diagnosis, and management of triple-negative, HER2-positive, and hormone receptor-positive breast cancers. Topics include molecular classification, biomarker-guided therapy, endocrine resistance, HER2-directed treatments, immunotherapy, antibody-drug conjugates, and emerging targeted therapies. Experts will discuss advances in precision medicine, treatment sequencing, neoadjuvant and adjuvant strategies, and ongoing clinical trials designed to improve outcomes for patients across all major breast cancer subtypes.

Track 17: Breast Cancer Awareness, Advocacy and Public Health

Public awareness, patient advocacy, and equitable access to healthcare remain vital in reducing the global impact of breast cancer. This session explores community outreach programs, awareness campaigns, screening initiatives, health policy, patient advocacy, survivorship support, and strategies to reduce disparities in breast cancer care. Discussions will focus on improving health literacy, promoting early diagnosis, strengthening patient engagement, and fostering collaborations among healthcare providers, advocacy organizations, researchers, and policymakers. Innovative public health initiatives that improve access to quality care and support underserved populations will also be highlighted.

Track 18: Future Innovations in Breast Cancer Research and Precision Medicine

Rapid scientific and technological advances continue to redefine the future of breast cancer research and clinical practice. This track highlights emerging innovations in precision oncology, multi-omics research, liquid biopsy, spatial biology, nanomedicine, gene editing, regenerative medicine, AI-assisted drug discovery, and next-generation therapeutics. Experts will discuss novel biomarkers, personalized vaccine development, digital clinical trials, and future directions in translational research. The session provides a forward-looking perspective on groundbreaking discoveries that are expected to transform breast cancer prevention, diagnosis, treatment, and survivorship over the coming decade.

Market Analysis

The global breast cancer therapeutics market continues to experience significant growth, driven by the increasing prevalence of breast cancer, advancements in precision oncology, and the development of innovative treatment strategies. Industry projections indicate that the market is expected to witness steady expansion through 2033, supported by a growing demand for targeted therapies, immunotherapies, hormone-based treatments, and personalized medicine approaches.

The market encompasses a broad spectrum of pharmaceutical and biotechnology innovations aimed at improving the diagnosis, treatment, and long-term management of breast cancer. Continuous investments in research and development have accelerated the introduction of novel drug candidates, antibody-drug conjugates (ADCs), PARP inhibitors, CDK4/6 inhibitors, and next-generation immunotherapies, offering improved survival outcomes and quality of life for patients.

Increasing awareness of early detection, expanding access to advanced healthcare services, favorable regulatory initiatives, and the integration of artificial intelligence and genomic profiling into clinical decision-making are further transforming the breast cancer care landscape. Additionally, the growing emphasis on precision medicine and biomarker-driven therapies is enabling more individualized treatment strategies across different breast cancer subtypes.

With ongoing clinical trials, global collaborations between academia and industry, and rising investments from pharmaceutical and biotechnology companies, the breast cancer therapeutics market is expected to maintain robust growth in the coming years. These developments highlight the importance of international scientific platforms such as the Breast Cancer Summit 2027, where researchers, clinicians, oncologists, industry leaders, and healthcare professionals can exchange knowledge, present groundbreaking discoveries, and foster collaborations that will shape the future of breast cancer prevention, diagnosis, and treatment.